Monopar Therapeutics Inc. announced the appointment of Laura Kelly as Director of Clinical Operations. Ms. Kelly will be responsible for managing Monopar’s clinical programs, including the recently launched Phase 2b/3 VOICE trial for the Company’s lead drug candidate Validive®. Ms. Kelly brings a wealth of clinical research experience, including oncology and the execution of Phase 1 through Phase 4 clinical trials, to the Monopar team. Prior to Monopar, Ms. Kelly served in strategic and clinical operation leadership roles at Merck/EMD Serono, AbbVie, Abbott Labs, and Amgen.